The Effect of Adjuvant Intravitreal Dexametason to Visual Outcomes of Acute Bacterial Endophthalmitis: A Ten Years Systematic Review

The Effect of Adjuvant Intravitreal Dexametason to Visual Outcomes of Acute Bacterial Endophthalmitis

A Ten Years Systematic Review

Authors

  • Felia Lianda Faculty of Medicine, Sultan Agung Islamic University, Indonesia
  • Tri Hendro Priyanto Opthalmology Consultant, SMEC Eye Health Service Centre Clinic, Indonesia

Keywords:

Endophthalmitis, dexamethasone, adjuvant, intravitreal, acute

Abstract

Background: Endophthalmitis is a rare but potentially visually devastating condition that is defined as infection in the intraocular cavities (i.e. aqueous or vitreous humor, or both). Methods: This systematic review focused on full-text English literature published between 2014 and 2024 using the PRISMA 2020 guidelines. Editorials and review pieces published in the same journal as the submission without a DOI were not accepted. The literature was compiled using PubMed, ScienceDirect, and SagePub, among other online venues. Result: Five publications were found to be directly related to our ongoing systematic examination after a rigorous three-level screening approach. Subsequently, a comprehensive analysis of the complete text was conducted, and additional scrutiny was given to these articles. Conclusion: Intravitreal dexamethasone does not provide additional visual benefits to endophthalmitis patients.

References

Soekamto C, Rosignoli L, Zhu C, Johnson D, Sohn JH, Bahadorani S. Visual outcomes of acute bacterial endophthalmitis treated with adjuvant intravitreal dexamethasone: A meta-analysis and systematic review. Indian J Ophthalmol. 2022;70(8):2835.

Schwartz S, Vaziri K, Kishor K, Flynn, Jr. HW. Endophthalmitis: state of the art. Clin Ophthalmol. 2015 Jan;95.

Emami S, Kitayama K, Coleman AL. Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database Syst Rev. 2022;2022(6).

Azhari J, Tetelbom PS, Sallam AB. The Role of Adjuvant Systemic and Intravitreal Corticosteroids in Fungal Endophthalmitis Treatment. J Fungi. 2023;9(12).

Goel N. Acute bacterial endophthalmitis following intravitreal dexamethasone implant: A case report and review of literature. Saudi J Ophthalmol [Internet]. 2017;31(1):51–4. Available from: http://dx.doi.org/10.1016/j.sjopt.2016.12.003

Al Zamil W, Yassin S. Acute bacterial endophthalmitis following dexamethasone intravitreal implant: A case report. Saudi J Med Med Sci. 2019;7(2):110.

Moisseiev E, Abbassi S, Park SS. Intravitreal dexamethasone in the management of acute endophthalmitis: A comparative retrospective study. Eur J Ophthalmol. 2017;27(1):67–73.

Conrady CD, Feist RM, Vitale AT, Shakoor A. Long-term visual outcomes of endophthalmitis and the role of systemic steroids in addition to intravitreal dexamethasone. BMC Ophthalmol. 2020;20(1):4–11.

Manning S, Ugahary LC, Lindstedt EW, Wubbels RJ, van Dissel JT, Jansen JTG, et al. A prospective multicentre randomized placebo-controlled superiority trial in patients with suspected bacterial endophthalmitis after cataract surgery on the adjuvant use of intravitreal dexamethasone to intravitreal antibiotics. Acta Ophthalmol. 2018;96(4):348–55.

Koehrer P, Bron AM, Chiquet C, Thuret G, Delbosc B, Berrod JP, et al. Early versus delayed intravitreal betamethasone as an adjuvant in the treatment of presumed postoperative endophthalmitis: A randomised trial. Br J Ophthalmol. 2016;100(8):1076–80.

Lindstedt EW, Bennebroek CA, van der Werf DJ, Veckeneer M, Norel AO van, Nielsen CCM, et al. A prospective multicenter randomized placebo-controlled trial of dexamethasone as an adjuvant in the treatment of postoperative bacterial endophthalmitis: interim safety analysis of the study drug and analysis of overall treatment results. Graefe’s Arch Clin Exp Ophthalmol. 2014;252(10):1631–7.

Shao EH, Yates WB, Ho I Van, Chang AA, Simunovic MP. Endophthalmitis: Changes in Presentation, Management and the Role of Early Vitrectomy. Ophthalmol Ther [Internet]. 2021;10(4):877–90. Available from: https://doi.org/10.1007/s40123-021-00406-6

Kim J, Kim HS, Yoo SJ, Choi MJ, Lew Y, Kim JW, et al. Immediate Vitrectomy for Acute Endophthalmitis in Patients with a Visual Acuity of Hand Motion or Better. Korean J Ophthalmol. 2022;36(5):390–7.

Sadiq MA, Hassan M, Agarwal A, Sarwar S, Toufeeq S, Soliman MK, et al. Endogenous endophthalmitis: diagnosis, management, and prognosis. J Ophthalmic Inflamm Infect [Internet]. 2015;5(1):1–11. Available from: http://dx.doi.org/10.1186/s12348-015-0063-y

Theelen T, Tilanus MAD. Treatment of Acute Bacterial Endophthalmitis After Cataract Surgery Without Vitrectomy. Vitr Surg. 2007;69–83.

Ong AY, Rigaudy A, Toufeeq S, Robins J, Shalchi Z, Bindra MS, et al. Intravitreal injections as a leading cause of acute postoperative endophthalmitis—a regional survey in England. Eye. 2023;37(1):163–9.

Published

2024-05-17

Issue

Section

Articles

How to Cite

Lianda, Felia, and Tri Hendro Priyanto. 2024. “The Effect of Adjuvant Intravitreal Dexametason to Visual Outcomes of Acute Bacterial Endophthalmitis: A Ten Years Systematic Review”. The International Journal of Medical Science and Health Research 1 (2): 202-15. https://internationalmedicaljournal.org/index.php/ijmhsr/article/view/15.